Nawras Al-Taie1, Delia Maftei2, Alexandra Kautzky-Willer3, Michael Krebs3, Harald Stingl2. 1. Department of Internal Medicine, Center for Diabetes and Metabolic Diseases, Melk, Austria. nawras.altaie@reflex.at. 2. Department of Internal Medicine, Center for Diabetes and Metabolic Diseases, Melk, Austria. 3. Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Abstract
BACKGROUND: Assessing the quality of life (QOL) for patients with type 2 diabetes is an essential part of diabetes management, especially for the evaluation of new antidiabetic treatments and glucose monitoring technologies. Accordingly, the aim of this study was to assess QOL according to treatment types. METHODS: This cross-sectional study included 170 patients with type 2 diabetes from the region of Melk in Lower Austria. Of the patients 61 used only oral antidiabetic agents (OAD) and 109 patients were treated with insulin (with or without OAD). The QOL was assessed in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors). Among the 170 patients with type 2 diabetes 95 used SGLT2 inhibitors. The World Health Organization Quality of Life BREF (WHOQOL-BREF) assessment was used to assess QOL among these patients. The Mann-Whitney U-test was utilized in this study and a P value <0.05 was considered statistically significant. RESULTS: Regarding the 170 participants, most were male (58.82%) and the mean glycated hemoglobin (HbA1c) level was 55.46 ± 12.30 mmol/mol (7.2%). The WHOQOL-BREF scores among type 2 diabetes patients were relatively high, which reflect a good QOL and the mean physical, psychological, social and environmental domain scores were 64.53 ± 20.15, 71.29 ± 18.08, 70.10 ± 20.08, and 84.419 ± 11.22 SD, respectively. There were no statistically significant differences in WHOQOL scores of the domains between the insulin-treated group and OAD group and between the group treated with SGLT2 inhibitors and the group not treated with SGLT2 inhibitors. CONCLUSION: This study showed no QOL distinctions between treatment groups in patients with type 2 diabetes; however, a large cohort study is needed to examine these groups further.
BACKGROUND: Assessing the quality of life (QOL) for patients with type 2 diabetes is an essential part of diabetes management, especially for the evaluation of new antidiabetic treatments and glucose monitoring technologies. Accordingly, the aim of this study was to assess QOL according to treatment types. METHODS: This cross-sectional study included 170 patients with type 2 diabetes from the region of Melk in Lower Austria. Of the patients 61 used only oral antidiabetic agents (OAD) and 109 patients were treated with insulin (with or without OAD). The QOL was assessed in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors). Among the 170 patients with type 2 diabetes 95 used SGLT2 inhibitors. The World Health Organization Quality of Life BREF (WHOQOL-BREF) assessment was used to assess QOL among these patients. The Mann-Whitney U-test was utilized in this study and a P value <0.05 was considered statistically significant. RESULTS: Regarding the 170 participants, most were male (58.82%) and the mean glycated hemoglobin (HbA1c) level was 55.46 ± 12.30 mmol/mol (7.2%). The WHOQOL-BREF scores among type 2 diabetespatients were relatively high, which reflect a good QOL and the mean physical, psychological, social and environmental domain scores were 64.53 ± 20.15, 71.29 ± 18.08, 70.10 ± 20.08, and 84.419 ± 11.22 SD, respectively. There were no statistically significant differences in WHOQOL scores of the domains between the insulin-treated group and OAD group and between the group treated with SGLT2 inhibitors and the group not treated with SGLT2 inhibitors. CONCLUSION: This study showed no QOL distinctions between treatment groups in patients with type 2 diabetes; however, a large cohort study is needed to examine these groups further.
Entities:
Keywords:
Diabetes, type 2; HbA1c; Quality of life; SGLT2 inhibitors; WHOQOL-BREF
Authors: Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil Journal: N Engl J Med Date: 2008-09-10 Impact factor: 91.245
Authors: Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri Journal: Diabetes Res Clin Pract Date: 1995-05 Impact factor: 5.602